PMID- 36322877
OWN - NLM
STAT- MEDLINE
DCOM- 20221201
LR  - 20221201
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 23
IP  - 17
DP  - 2022 Dec
TI  - Contemporary choice of glucose lowering agents in heart failure patients with 
      type 2 diabetes.
PG  - 1957-1974
LID - 10.1080/14656566.2022.2143263 [doi]
AB  - INTRODUCTION: There is a bi-directional link between type 2 diabetes mellitus 
      (T2DM) and heart failure (HF) and their co-existence markedly increases an 
      individual's morbidity and mortality. Therefore, it is of major importance to 
      diagnose early (and, even better, prevent) HF in T2DM patients, as well as 
      adequately treat T2DM patients with HF. AREAS COVERED: The present narrative 
      review discusses the effects of different antidiabetic drugs [metformin, 
      pioglitazone, sulphonylureas (SUs), dipeptidyl peptidase 4 inhibitors (DPP4i), 
      glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose 
      cotransporter 2 inhibitors (SGLT2i) and insulin] on HF incidence, hospitalization 
      and outcomes. Current guidelines of diabetes and cardiology societies on this 
      issue are also commented on. EXPERT OPINION: Metformin (+lifestyle interventions) 
      is the first-line treatment for all T2DM patients and SGLT2i are the preferred 
      drugs (class I, level of evidence A) in patients with T2DM and HF. Pioglitazone 
      is contraindicated in HF, whereas SUs, DPP4i, GLP-1 RAs and insulin are 
      considered as neutral. However, SUs may cause hypoglycemia and weight gain, 
      saxagliptin (a DPP4i) must be avoided in this setting and GLP-1 RAs seem not to 
      affect HF risk. There is an urgent need of increasing guidelines implementation 
      regarding SGLT2i use in clinical practice, to sufficiently tackle the HF burden 
      in T2DM.
FAU - Katsiki, Niki
AU  - Katsiki N
AD  - Department of Nutritional Sciences and Dietetics, International Hellenic 
      University, Thessaloniki, Greece.
AD  - School of Medicine, European University Cyprus, Nicosia, Cyprus.
FAU - Kazakos, Kyriakos
AU  - Kazakos K
AD  - Nursing Department, International Hellenic University, Thessaloniki, Greece.
FAU - Triposkiadis, Filippos
AU  - Triposkiadis F
AD  - Department of Cardiology, University General Hospital of Larissa, Larissa, 
      Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221120
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - IY9XDZ35W2 (Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 9100L32L2N (Metformin)
RN  - X4OV71U42S (Pioglitazone)
RN  - 0 (Sulfonylurea Compounds)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Glucose
MH  - *Heart Failure/drug therapy/epidemiology
MH  - *Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Metformin/therapeutic use
MH  - Pioglitazone/adverse effects
MH  - Sulfonylurea Compounds/therapeutic use
MH  - Contraindications, Drug
OTO - NOTNLM
OT  - dipeptidyl peptidase 4 inhibitors
OT  - glucagon-like peptide-1 receptor agonists
OT  - heart failure
OT  - insulin
OT  - metformin
OT  - pioglitazone
OT  - sodium-glucose cotransporter 2 inhibitors
OT  - sulphonylureas
OT  - type 2 diabetes mellitus
EDAT- 2022/11/03 06:00
MHDA- 2022/12/01 06:00
CRDT- 2022/11/02 16:03
PHST- 2022/11/03 06:00 [pubmed]
PHST- 2022/12/01 06:00 [medline]
PHST- 2022/11/02 16:03 [entrez]
AID - 10.1080/14656566.2022.2143263 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2022 Dec;23(17):1957-1974. doi: 
      10.1080/14656566.2022.2143263. Epub 2022 Nov 20.